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Objective  To evaluate pulmonary functions of patients with amyotrophic lateral sclerosis (ALS), Duchenne 
muscular dystrophy (DMD), and myotonic muscular dystrophy (MMD) at the onset of ventilatory insufficiency.
Methods  This retrospective study included ALS, DMD, and MMD patients with regular outpatient clinic follow-
up in the Department of Rehabilitation Medicine at Gangnam Severance Hospital before the application of non-
invasive positive pressure ventilation (NIPPV). The patients were enrolled from August 2001 to March 2014. If 
patients experienced ventilatory insufficiency, they were treated with NIPPV, and their pulmonary functions were 
subsequently measured.
Results  Ninety-four DMD patients, 41 ALS patients, and 21 MMD patients were included in the study. The mean 
SpO2 was lower in the MMD group than in the other two groups. The mean forced vital capacity (FVC) in the 
supine position was approximately low to mid 20% on average in DMD and ALS patients, whereas it was 10% 
higher in MMD patients. ALS patients showed a significantly lower FVC in the supine position than in the sitting 
position. Maximal insufflation capacity, unassisted peak cough flow, maximum inspiratory pressure (MIP), and 
maximum expiratory pressure (MEP) were significantly higher in MMD group than in the other groups. MEP was 
significantly the lowest in DMD patients, followed by in ALS, and MMD patients, in order.
Conclusion  Disease-specific values of pulmonary function, including FVC, MEP, and MIP, can be accurately used 
to assess the onset of ventilatory insufficiency in patients with ALS, DMD, and MMD.
Keywords  Neuromuscular diseases, Respiratory insufficiency, Duchenne muscular dystrophy, Amyotrophic 
lateral sclerosis, Myotonic dystrophy
Pulmonary Functions at Ventilatory Insufficiency Time in ALS, DMD, MMD
75www.e-arm.org
INTRODUCTION
In patients with neuromuscular disease, respiratory 
muscle weakness and elastic load are responsible for 
rapid and shallow breathing patterns that lead to chronic 
CO2 retention [1]. Adequate and timely ventilatory sup-
port, such as non-invasive ventilation in secondary 
hypercapnic ventilatory insufficiency caused by neu-
romuscular diseases, can reduce respiratory morbidity 
and mortality. However, it is difficult to detect the point 
at which CO2 retention begins. The early symptoms of 
persistent hypercapnia include nightmares, morning 
headaches, daytime drowsiness, and generalized fatigue, 
dyspnea at rest, orthopnea, and paradoxical breathing 
patterns [2-4]. These symptoms are highly subjective and 
insignificant. Therefore, CO2 retention could be severe by 
the time the patient complains of such symptoms [5]. 
Additionally, the ventilation status worsens during 
nighttime sleeping due to decreased respiratory center 
function. Even if CO2 retention occurs at night, the arte-
rial blood gas analysis and end-tidal CO2 (EtCO2) levels 
may appear normal during the day in outpatient clinics. 
Continuous and non-invasive CO2 monitoring during the 
night is useful for the evaluation of accurate ventilation 
status and the detection of ventilatory insufficiency; how-
ever, this requires hospitalization. 
Patients with neuromuscular diseases show restrictive 
lung disease patterns due to weakness of the respira-
tory muscles. Previous research has determined values 
for various pulmonary functions that could be used as 
screening tools to detect the precise point of ventilatory 
insufficiency. Specifically, hypercapnia reportedly occurs 
in patients with neuromuscular diseases when respira-
tory muscle strength parameters, such as the maximum 
inspiratory pressure (MIP) and maximum expiratory 
pressure (MEP), decrease to <30% of the normal value, or 
when the forced vital capacity (FVC) is reduced to below 
55% of the predicted value [6]. Another report suggested 
that hypercapnia occurs when FVC is 500–700 mL [2]. 
However, neuromuscular disease is a broad term that 
encompasses many syndromes, and these diseases do 
not show identical conditions at the onset of ventilatory 
insufficiency. Additionally, there are no broadly accepted 
disease-specific screening values for ventilatory insuffi-
ciency. 
Therefore, we included patients with amyotrophic 
lateral sclerosis (ALS), Duchenne muscular dystrophy 
(DMD), and myotonic muscular dystrophy (MMD), 
which are relatively common neuromuscular diseases, to 
determine clinically relevant pulmonary functions at the 
onset of ventilatory insufficiency. 
MATERIALS AND METHODS
Subjects
This retrospective study included ALS, DMD, and 
MMD patients who were treated with non-invasive posi-
tive pressure ventilation (NIPPV) for the first time dur-
ing hospitalization in the Department of Rehabilitation 
Medicine at Gangnam Severance Hospital from August 
2001 to March 2014. Patients with regular follow-up at the 
outpatient clinic prior to NIPPV treatment were enrolled 
and the hospitalization period was determined.
Patients who did not receive a confirmative diagnosis 
(even if 1 of the 3 diagnoses was clinically suspected) and 
those who had other accompanying diseases that may 
have affected respiration, such as Parkinson disease or 
chronic obstructive pulmonary disease, were excluded. 
Additionally, patients who were hospitalized immedi-
ately at their first visit to the hospital due to previous CO2 
retention symptoms or high EtCO2, as well as the patients 
in whom invasive ventilator was the first interface used 
for respiration, such as in tracheostomy or intubation, 
were excluded from the study.
Detection of ventilatory insufficiency and application 
of NIPPV
Patients were hospitalized if there were CO2 retention 
symptoms or if the simplified EtCO2 level measured on 
the spot was ≥40 mmHg than those from regular follow-
ups in the outpatient clinic. After hospitalization, cap-
illary CO2 level and oxygen saturation were measured 
through continuous and non-invasive monitoring of res-
piration during nighttime sleeping hours. The CO2 partial 
pressure of the capillary vessels (pCO2) was directly and 
percutaneously measured through the SenTec system 
(SenTec AG, Therwil, Switzerland) or indirectly measured 
by the EtCO2 level through the DASH Series (GE Health-
care, Milwaukee, WI, USA). Ventilatory insufficiency was 
identified as present when the maximum CO2 level was 
>40 mmHg or the oxygen saturation was <95%; NIPPV 
was then applied [7]. The study was conducted when 
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ventilatory insufficiency was present.
Evaluation of pulmonary function
Pulmonary function was measured immediately after 
the detection of ventilatory insufficiency. FVC and maxi-
mal insufflation capacity (MIC) were measured in the 
sitting and supine positions using a hand-held spirom-
eter (Micro Medical Ltd., Rochester, Kent, UK). FVC was 
expressed as a percentage of the predicted normal value 
[8,9]. 
In order to measure MIC, the patient was asked to in-
hale as much air as possible; then, an extra volume of air 
was delivered by a manual resuscitator bag using either 
an oronasal mask or a mouthpiece. After holding in the 
additional air, the patient was asked to exhale as much 
air as possible into the spirometer. 
Peak cough flow (PCF) was measured using a peak-flow 
meter (Philips Respironics, Guildford, UK). Unassisted 
PCF (UPCF) was measured by asking the patient to inhale 
as much air as possible and then cough heavily. Assisted 
PCF (APCF) was measured with the tester thrusting the 
patient’s abdomen when the patient coughed in the MIC 
state. 
MIP and MEP, which are indicators of the strength of 
the respiratory muscles, were also measured in the sit-
ting and supine positions using a mouth pressure meter 
(Micro Medical Ltd.). Measurements were expressed as 
the percentage of the predicted value, using Wilson and 
Cooke’s data [10].
All measurements were performed at least thrice. The 
highest positive value of FVC, MIC, UPCF, APCF, and 
MEP and the lowest negative value for MIP were included 
in the analysis.
Statistical analysis
Statistical analysis was performed using SPSS ver. 20.0 
(IBM Corp., Armonk, NY, USA). The normality of the dis-
tribution of the variables was assessed using the Shapiro–
Wilk test. The Kruskal–Wallis test was used to analyze the 
differences among the 3 study groups. Using the Mann–
Whitney U test, multiple comparison analyses between 
2 different groups were performed with Bonferroni cor-
rection as a post-hoc test. Moreover, in each study group, 
the differences in FVC between the sitting and supine 
positions were analyzed with a paired t-test. All tests were 
two-sided, and p-values <0.05 were considered statisti-
cally significant.
RESULTS
General characteristics of the study groups
A total of 156 patients were included in the present 
study, of which 94 had DMD, 41 had ALS, and 21 had 
MMD. The mean age of the patient groups was 18.1, 55.9, 
and 42.7 years, respectively, with significant differences 
among the 3 groups (Tables 1, 2). There were 17 male pa-
tients with ALS (41.5%) and 11 with MMD (52.4%) (Table 1).
Continuous monitoring of ventilatory status during 
nighttime sleep 
The maximal value of pCO2 throughout the continuous 
monitoring during nighttime sleep showed no significant 
group-wise differences. The mean saturation of periph-
eral oxygen was lower in the MMD group than in the 
other 2 groups. The mean saturation of peripheral oxygen 
was significantly lower in MMD patients than in DMD 
patients (p=0.045).
Evaluation of pulmonary function
There was a significant difference in FVC in the sitting 
(FVC_sit(%)) and supine (FVC_sup(%)) positions among 
the 3 groups (Table 2). ALS and MMD patients showed 
Table 1. General characteristics of the study groups
DMD (n=94) ALS (n=41) MMD (n=21) Total (n=156)
Age (yr) 18.1±3.9 55.9±10.1 42.7±10.6 31.4±18.2
Sex (male:female) 94:0 17:24 11:10 122:34
FVC_sit (mL) 951.0±492.0 1,165.2±504.3 1,806.5±825.8 1,124.5±617.0
FVC_sup (mL) 930.2±498.2 989.5±451.0 1,703.0±854.0 1,050.7±602.2
Values are presented as mean±standard deviation or number.
DMD, Duchenne muscular dystrophy; ALS, amyotrophic lateral sclerosis; MMD, myotonic muscular dystrophy; FVC_
sit, forced vital capacity at sitting position; FVC_sup, forced vital capacity at supine position.
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significantly higher values of FVC_sit(%), as compared 
to the DMD patients. FVC_sit(%) was 23.5%±9.8% in 
the DMD group, 31.4%±10.1% in the ALS group, and 
39.9%±13.0% in the MMD group (p=0.042 for DMD vs. 
ALS; p<0.001 for DMD vs. MMD). This value was also 
higher in the MMD group than in the ALS group; how-
ever, the difference was not statistically significant. The 
mean FVC_sup(%) was similar for the DMD and ALS 
patients, with no significant difference between the 2 
groups (FVC_sit(%)=22.5%±10.4% for DMD, FVC_sup(%) 
=24.8%±8.4% for ALS). However, the mean FVC_sup(%) 
was about 10% higher in MMD group than in the other 2 
groups, which was statistically significant (FVC_sup(%) 
=34.7%±10.0% for MMD). As for FVC by position, ALS 
patients showed a significantly higher FVC_sit(%) than 
FVC_sup(%) (FVC_sit(%)=31.4%±10.1%, FVC_sup(%)= 
24.8%±8.4%, p<0.001). In DMD and MMD patients, there 
was no statistically significant difference in FVC between 
the 2 positions. 
MIC and UPCF were higher in MMD patients than in 
the other patient groups, whereas APCF showed no sig-
nificant difference among the 3 groups. 
MIP and MEP were also significantly higher in MMD 
patients than in the other groups. MEP was significantly 
lowest in DMD patients, followed by ALS patients, and 
MMD patients, in order.
In DMD patients, MEP was significantly lower than 
MIP regardless of the position (MEP in sitting position 
=15.4±4.8 mmHg, MIP in sitting position=24.0±13.4 
mmHg, p<0.001; MEP in supine position=15.4±5.8 
Table 2. Comparisons of various measurements among the study groups
DMD ALS MMD
p-value
DMD vs. 
ALS
DMD vs. 
MMD
ALS vs. 
MMD
Among 
groups 
Age (yr) 17.4±2.5 56.8±5.3 43.8±6.6 <0.001 <0.001 <0.001 <0.001
Continuous monitoring of ventila-
tor status during sleep time
   Max_CO2 (mmHg) 50.3±3.1 52.7±5.1 52.0±6.2 0.666 0.177 1.000 0.127
   Mean_SpO2 (%) 97.0±1.1 96.0±1.9 95.0±3.0 0.357 0.045 0.453 0.022
Evaluations for pulmonary 
  function
   FVC_sit(%) 23.5±9.8 31.4±10.1 39.9±13.0 0.042 <0.001 0.099 <0.001
   FVC_sup(%) 22.5±10.4 24.8±8.4 34.7±10.0 0.696 0.003 0.030 0.003 
      p-value (FVC_sit vs. sup)    0.074 <0.001 0.066
   MIC (mL) 1,540±329 1,835±622 2,680±860 0.141 <0.001 0.045 <0.001
   UPCF (L/min) 175±48 145±55 260±65 1.000 <0.001 0.003 <0.001
   APCFmic (L/min) 290±53 270±87 340±85 1.000 0.093 0.456 0.120 
   MIP_sit(%) 24.0±13.4 25.2±9.0 41.6±12.2 1.000 0.003 0.006 0.002 
   MEP_sit(%) 15.4±4.8 26.1±12.8 37.3±8.7 <0.001 <0.001 0.252 <0.001
      p-value (MIP_sit vs. MEP_sit) <0.001    0.666 0.051
   MIP_sup(%) 25.0±12.5 23.6±7.6 35.8±15.9 1.000 0.066 0.015 0.019 
   MEP_sup(%) 15.4±5.8 23.7±11.3 37.0±8.7 0.012 <0.001 0.015 <0.001
      p-value (MIP_sup vs. MEP_sup) <0.001    0.789 0.447
Values are presented as mean±standard deviation.
DMD, Duchenne muscular dystrophy; ALS, amyotrophic lateral sclerosis; MMD, myotonic muscular dystrophy; FVC_
sit(%), a percent of the predicted value of forced vital capacity at sitting position; FVC_sup(%), a percent of the predict-
ed value of forced vital capacity at supine position; MIC, maximal insufflation capacity; UPCF, unassisted peak cough 
flow; APCF, assisted peak cough flow; MIP_sit(%), a percent of the predicted value of maximum inspiratory pressure 
at sitting position; MIP_sup(%), a percent of the predicted value of maximal inspiratory pressure at supine position; 
MEP_sit(%), a percent of the predicted value of maximum expiratory pressure at sitting position; MEP_sup(%), a per-
cent of the predicted value of maximum expiratory pressure at supine position.
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mmHg, MIP in supine position=25.0±12.5 mmHg, 
p<0.001). In patients with MMD, MEP was lower than 
MIP in the sitting position but not in the supine position; 
however, the difference was not statistically significant. 
Additionally, MEP and MIP showed no significant differ-
ences in ALS patients. 
DISCUSSION
Neuromuscular disease refers to a variety of diseases 
that adversely affect the nerves and muscles and may 
indicate multiple diagnoses, with a range of potential 
clinical courses according to each diagnosis. The mecha-
nism of ventilatory insufficiency varies according to the 
specific type of neuromuscular disease. By comparing 
the pulmonary functions at the onset of ventilatory in-
sufficiency in different types of neuromuscular diseases, 
we determined the distinctive characteristics for each of 
these diseases and the specific points to consider during 
ventilator application. 
The results of this study suggested that patients should 
be closely observed when their pulmonary function val-
ues fall below the specific cutoff values. In case of DMD, 
ventilatory insufficiency occurred on average when FVC 
and MIP were approximately 20%–25% and MEP was 
about 15% of the patient’s normal values. Therefore, 
close observation is required if FVC, MEP, and MIP drop 
below 40%, 30%, and 40% of the patient’s normal values, 
respectively, in either the supine or sitting positions. For 
ALS, ventilatory insufficiency occurred when the supine 
FVC, MEP, and MIP were approximately 20%–25% of the 
patient’s normal values; thus, close observation is need-
ed if FVC, MEP, and MIP drop below 40% of the patient’s 
normal values in the supine position. Ventilatory insuf-
ficiency began in MMD patients when the supine FVC 
was about 35% of the normal values, hence these patients 
require closer attention than DMD or ALS patients. Thus, 
close observation is needed for MMD patients when the 
supine FVC drops below 50% of the patient’s normal val-
ues. 
Unlike the results of our study, a previous study re-
ported that hypercapnia occurs when respiratory muscle 
strength is <30% and FVC drops below 55% of the pre-
dicted value in patients with neuromuscular diseases [6]. 
However, the previous study included patients with non-
specific neuromuscular diseases; thus, the difference in 
the patients’ homogeneity may have led to the conflicting 
results.
In the present study, MMD patients showed earlier 
ventilatory insufficiency than the other 2 patient groups 
despite their well-preserved pulmonary functions. This 
result is in agreement with that of a previous study, which 
suggested that ventilatory insufficiency could occur when 
respiratory muscle weakness is not pronounced in MMD 
patients [11]. Our study also showed that many param-
eters other than FVC (e.g., MEP, MIP, or PCF) are better 
preserved in MMD patients, as compared with the other 
2 patient groups.
There are 2 main reasons other than respiratory muscle 
weakness for such disproportionate rates of ventilatory 
insufficiency in MMD patients. First, delayed relaxation 
may occur in the respiratory muscles as it does in other 
muscles in MMD patients. One study verified the delayed 
relaxation of the diaphragm using fluoroscopy [12], and 
another confirmed the myotonic movement of the respi-
ratory muscles, including the diaphragm, through elec-
tromyography [11,13]. Another possibility is that MMD 
patients have trouble with central respiratory control [14]. 
One study suggested that the high incidence of ventilato-
ry insufficiency in MMD patients is related to a decreased 
hypoxic ventilatory response due to an underlying neuro-
genic deficit [15]. Another study suggested that neuronal 
loss in the medullary arcuate nucleus is associated with 
hypoventilation in myotonic dystrophy [16]. 
However, there has been insufficient research on 
whether the myotonic movement of respiratory muscles 
actually causes ventilatory insufficiency; and there are 
still many controversies concerning the main factors in-
volved. In the present study, the mean saturation of pe-
ripheral oxygen tended to be lower in MMD patients than 
the other groups, which indicates the possibility of sleep 
apnea. Further evaluation including polysomnography is 
needed. 
Although sitting FVC was higher in ALS patients, there 
were no significant differences in the predictive value 
of supine FVC between ALS and DMD patients. This in-
dicates that ALS patients exhibit significant differences 
in FVC between the sitting and supine positions, unlike 
those of the other patient groups. FVC also tends to be 
lower in the supine position for healthy people because 
the abdominal contents press on the diaphragm in this 
position, thus increasing the amount of pulmonary circu-
Pulmonary Functions at Ventilatory Insufficiency Time in ALS, DMD, MMD
79www.e-arm.org
lation and reducing the volume of air entering the thorax 
[17]. However, this lower value of supine FVC is greater in 
ALS patients because of the weakness of the diaphragm 
[18,19]. Therefore, FVC should be measured in the supine 
position in ALS patients. Loss in diaphragmatic strength 
is spared until the very late stages of DMD [20,21], and 
consequently, the fall in supine FVC is not generally ob-
vious in DMD patients.
Lastly, MEP was less than MIP in both DMD and MMD 
patients in the sitting position. Previous studies have 
revealed that the first indication of pulmonary dys-
function in DMD and MMD populations is a decline in 
MEP [14,22,23]. Thus, MEP should be considered when 
screening for ventilatory insufficiency in DMD and MMD 
patients. 
The limitations of this study were that the patient group 
included only 3 diseases and a relatively small number of 
patients were enrolled in the MMD group, as compared 
with the other 2 groups. Further studies are needed to re-
veal the pulmonary functions and mechanisms contrib-
uting to ventilatory insufficiency in these and other types 
of neuromuscular diseases.
In conclusion, pulmonary functions at the onset of 
ventilatory insufficiency differ in ALS, DMD, and MMD 
patients according to the different characteristics of each 
disease. Disease-specific pulmonary values (including 
FVC, MEP, and MIP) could be used to accurately screen 
for ventilatory insufficiency.
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